See more : Alkhabeer REIT Fund (4348.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Senti Biosciences, Inc. (SNTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senti Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ESGold Corp. (SEKZF) Income Statement Analysis – Financial Results
- Genex Power Limited (GNX.AX) Income Statement Analysis – Financial Results
- Premier Development & Investment, Inc. (PDIV) Income Statement Analysis – Financial Results
- Ivanhoe Capital Acquisition Corp. (IVAN-UN) Income Statement Analysis – Financial Results
- Qianhe Condiment and Food Co., Ltd. (603027.SS) Income Statement Analysis – Financial Results
Senti Biosciences, Inc. (SNTI)
About Senti Biosciences, Inc.
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.56M | 4.29M | 2.29M | 394.00K | 85.00K |
| Cost of Revenue | 5.24M | 3.92M | 3.01M | 15.96M | 14.52M |
| Gross Profit | -2.68M | 366.00K | -719.00K | -15.56M | -14.44M |
| Gross Profit Ratio | -104.76% | 8.54% | -31.38% | -3,949.75% | -16,987.06% |
| Research & Development | 32.15M | 34.07M | 21.96M | 15.96M | 14.52M |
| General & Administrative | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Other Expenses | 27.69M | 12.42M | -470.00K | -172.00K | 0.00 |
| Operating Expenses | 95.29M | 74.92M | 42.74M | 25.09M | 7.39M |
| Cost & Expenses | 94.71M | 74.92M | 42.74M | 25.09M | 21.92M |
| Interest Income | 2.86M | 1.70M | 11.00K | 88.00K | 674.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.89M | 3.01M | 1.99M | 427.00K |
| EBITDA | -61.34M | -70.63M | -39.68M | -22.71M | -21.36M |
| EBITDA Ratio | -2,395.00% | -1,647.90% | -1,633.09% | -5,703.30% | -25,123.53% |
| Operating Income | -92.73M | -70.63M | -40.45M | -24.69M | -21.78M |
| Operating Income Ratio | -3,620.73% | -1,647.90% | -1,765.43% | -6,267.51% | -25,625.88% |
| Total Other Income/Expenses | 9.32M | 12.42M | -14.87M | 4.83M | 625.00K |
| Income Before Tax | -83.41M | -58.21M | -55.32M | -19.86M | -21.16M |
| Income Before Tax Ratio | -3,256.77% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| Income Tax Expense | 0.00 | -12.42M | 11.00K | 150.00K | 0.00 |
| Net Income | -92.92M | -58.21M | -55.32M | -19.86M | -21.16M |
| Net Income Ratio | -3,628.23% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| EPS | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| EPS Diluted | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| Weighted Avg Shares Out | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
| Weighted Avg Shares Out (Dil) | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
Senesco Announces up to $25.2 Million Equity Financing
Senesco’s Drug Candidate SNS01-T Selectively Kills Cancer Cells and Not Healthy Cells in Disease Models
Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial
Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting
Senesco Announces Reverse Stock Split
Senesco Announces $1.725 Million Equity Financing
Senesco Technologies Reports Fiscal Year 2013 Financial Results
Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
Source: https://incomestatements.info
Category: Stock Reports